TP53 Mutations are Associated with CD19 Negative Relapse and Inferior Outcomes after Blinatumomab in Adults with ALL.
Aldoss I, Li S, Zhang J, Clark MC, Agrawal V, Pourhassan H, Koller PB, Aribi A, Ali H, Blackmon A, Otoukesh S, Sandhu KS, Ball BJ, Arslan S, Artz AS, Amanam I, Al Malki MM, Salhotra A, Kovacsovics TJ, Murphy LA, Afkhami M, Ngo D, Tinajero J, Gu Z, Becker PS, Nakamura R, Stein AS, Marcucci G, Forman SJ, Pullarkat VA.
Aldoss I, et al. Among authors: gu z.
Blood Adv. 2025 Jan 16:bloodadvances.2024014986. doi: 10.1182/bloodadvances.2024014986. Online ahead of print.
Blood Adv. 2025.
PMID: 39820649